TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Alvotech And Advanz Pharma
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA

Alvotech and Advanz Pharma received marketing authorisations from the UK's MHRA for Gobivaz®, a biosimilar to Simponi®, covering four presentations for treating various immune-mediated diseases across the United Kingdom.

Insights
ALVO   positive

Successfully received marketing authorisations, expanding product portfolio and demonstrating development capabilities in biosimilar medicines